Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease.

Nakagawa N, Barron L, Gomez IG, Johnson BG, Roach AM, Kameoka S, Jack RM, Lupher ML Jr, Gharib SA, Duffield JS.

JCI Insight. 2016 Dec 8;1(20):e87446. doi: 10.1172/jci.insight.87446.

2.

Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis.

Dillingh MR, van den Blink B, Moerland M, van Dongen MG, Levi M, Kleinjan A, Wijsenbeek MS, Lupher ML Jr, Harper DM, Getsy JA, Hoogsteden HC, Burggraaf J.

Pulm Pharmacol Ther. 2013 Dec;26(6):672-6. doi: 10.1016/j.pupt.2013.01.008. Epub 2013 Feb 4.

PMID:
23380438
3.

PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis.

Duffield JS, Lupher ML Jr.

Drug News Perspect. 2010 Jun;23(5):305-15. doi: 10.1358/dnp.2010.23.5.1444206.

PMID:
20603654
4.

Investigational approaches to therapies for idiopathic pulmonary fibrosis.

Gomer RH, Lupher ML Jr.

Expert Opin Investig Drugs. 2010 Jun;19(6):737-45. doi: 10.1517/13543784.2010.484018. Review.

5.

Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo.

Castaño AP, Lin SL, Surowy T, Nowlin BT, Turlapati SA, Patel T, Singh A, Li S, Lupher ML Jr, Duffield JS.

Sci Transl Med. 2009 Nov 4;1(5):5ra13. doi: 10.1126/scitranslmed.3000111. Erratum in: Sci Transl Med. 2009 Nov 4;1(5):5ra13.

6.

Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations.

Lin SL, Castaño AP, Nowlin BT, Lupher ML Jr, Duffield JS.

J Immunol. 2009 Nov 15;183(10):6733-43. doi: 10.4049/jimmunol.0901473. Epub 2009 Oct 28.

7.

Targeting integrin structure and function in disease.

Staunton DE, Lupher ML, Liddington R, Gallatin WM.

Adv Immunol. 2006;91:111-57. Review.

PMID:
16938539
8.

Regulation of fibrosis by the immune system.

Lupher ML Jr, Gallatin WM.

Adv Immunol. 2006;89:245-88. Review.

PMID:
16682276
9.

Crystal structure of the A domain from complement factor B reveals an integrin-like open conformation.

Bhattacharya AA, Lupher ML Jr, Staunton DE, Liddington RC.

Structure. 2004 Mar;12(3):371-8.

10.

Cellular activation of leukocyte function-associated antigen-1 and its affinity are regulated at the I domain allosteric site.

Lupher ML Jr, Harris EA, Beals CR, Sui LM, Liddington RC, Staunton DE.

J Immunol. 2001 Aug 1;167(3):1431-9.

11.

NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding.

Huth JR, Olejniczak ET, Mendoza R, Liang H, Harris EA, Lupher ML Jr, Wilson AE, Fesik SW, Staunton DE.

Proc Natl Acad Sci U S A. 2000 May 9;97(10):5231-6.

12.

The linker phosphorylation site Tyr292 mediates the negative regulatory effect of Cbl on ZAP-70 in T cells.

Rao N, Lupher ML Jr, Ota S, Reedquist KA, Druker BJ, Band H.

J Immunol. 2000 May 1;164(9):4616-26.

13.

The Cbl proto-oncogene product negatively regulates the Src-family tyrosine kinase Fyn by enhancing its degradation.

Andoniou CE, Lill NL, Thien CB, Lupher ML Jr, Ota S, Bowtell DD, Scaife RM, Langdon WY, Band H.

Mol Cell Biol. 2000 Feb;20(3):851-67.

14.

Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions.

Chen AI, McAdam AJ, Buhlmann JE, Scott S, Lupher ML Jr, Greenfield EA, Baum PR, Fanslow WC, Calderhead DM, Freeman GJ, Sharpe AH.

Immunity. 1999 Dec;11(6):689-98.

15.

The RING finger domain of Cbl is essential for negative regulation of the Syk tyrosine kinase.

Ota S, Hazeki K, Rao N, Lupher ML Jr, Andoniou CE, Druker B, Band H.

J Biol Chem. 2000 Jan 7;275(1):414-22. Erratum in: J Biol Chem 2000 Feb 25;275(8):6046.

16.

The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor.

Lill NL, Douillard P, Awwad RA, Ota S, Lupher ML Jr, Miyake S, Meissner-Lula N, Hsu VW, Band H.

J Biol Chem. 2000 Jan 7;275(1):367-77.

17.

The Cbl protooncoprotein: a negative regulator of immune receptor signal transduction.

Lupher ML Jr, Rao N, Eck MJ, Band H.

Immunol Today. 1999 Aug;20(8):375-82. Review.

PMID:
10431158
18.

Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323.

Lupher ML Jr, Rao N, Lill NL, Andoniou CE, Miyake S, Clark EA, Druker B, Band H.

J Biol Chem. 1998 Dec 25;273(52):35273-81.

19.

The c-Cbl oncoprotein.

Lupher ML Jr, Andoniou CE, Bonita D, Miyake S, Band H.

Int J Biochem Cell Biol. 1998 Apr;30(4):439-44. Review.

PMID:
9675877
20.
21.

The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and binds to the Tyr292 negative regulatory phosphorylation site of ZAP-70.

Lupher ML Jr, Songyang Z, Shoelson SE, Cantley LC, Band H.

J Biol Chem. 1997 Dec 26;272(52):33140-4.

23.

The Cbl protooncogene product: from an enigmatic oncogene to center stage of signal transduction.

Miyake S, Lupher ML Jr, Andoniou CE, Lill NL, Ota S, Douillard P, Rao N, Band H.

Crit Rev Oncog. 1997;8(2-3):189-218. Review.

PMID:
9570294
24.

Supplemental Content

Loading ...
Support Center